Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yikang Buyuan Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Chinese Medicine Hospital affiliated to Capital Medical University. It is specifically indicated for the treatment of chronic fatigue syndrome (CFS), particularly when characterized by the TCM pattern of 'qi deficiency and blood stasis syndrome'. The preparation is designed to replenish vital energy (qi) and promote blood circulation to alleviate persistent fatigue and improve overall quality of life. It has been evaluated in clinical settings in China, including phase 4 observational case series, where its efficacy was assessed using standardized fatigue severity scales and quality-of-life questionnaires.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yikang Buyuan Granule.